title: [Clinical Efficacy of Dendritic Cells and Cytokine-induced Killer Cells Combined with Chemotherapy for Treating Newly diagnosed Multiple Myeloma and their Effect on Function of CD4(+) CD25(+) T Cells in Peripheral Blood].
abstract: OBJECTIVE
  To investigate the efficacy of dendritic cells and cytokine-induced killer cells (DC-CIK) combined with chemotherapy for treating newly diagnosed patients with multiple myeloma (MM) and their effect on cellular immune functions of CD4(+) CD25(+) Treg cells in peripheral blood after adoptive immunotherapy.
  
  
  METHODS
  Fouty two patients with MM were randomly divided into two groups: chemotherapy group and combined therapy group; 20 patients in chemotherapy group were treated by chemotherapy only, 22 patients in combined therapy group were treated by adoptive immunotherapy (DC-CIK) combined with chemotherapy, and the clinical outcomes of patients and the levels of CD4(+) CD25(+) Treg cells in peripheral blood between 2 groups were compared.
  
  
  RESULTS
  After treating for 3 weeks, the quality of life, clinical index and survival of patients in combined therapy group were better than those of patients in chemotherapy group (P < 0.05); the ratios of CD4(+) CD25(+)/CD4(+) and CD4(+) CD25(+) FoxP3(+)/CD4(+) CD25(+) of patients in combined therapy group were obviously lower than those of patients in chemotherapy group (P < 0.05).
  
  
  CONCLUSIONS
  The immunotherapy of DC-CIK can strengthen the activities of CD4(+) CD25(+) Treg cells, which combined with chemotherapy can be an effective and promising effects for treatment of patients with MM.
authors.affiliation: Department of Hematology, The Central Hospital of Shengli Oil Field, Dongying 257034, Shandong Province, China.
authors.forename: Xia
authors.initials: X
authors.lastname: Zhao
authors.affiliation: Department of Hematology, The Central Hospital of Shengli Oil Field, Dongying 257034, Shandong Province, China.
authors.forename: Hui-Fang
authors.initials: HF
authors.lastname: Ding
authors.affiliation: Department of Hematology, The Central Hospital of Shengli Oil Field, Dongying 257034, Shandong Province, China.
authors.forename: Min
authors.initials: M
authors.lastname: Xu
authors.affiliation: Department of Hematology, The Central Hospital of Shengli Oil Field, Dongying 257034, Shandong Province, China.
authors.forename: Jian
authors.initials: J
authors.lastname: Xing
authors.affiliation: Department of Hematology, The Central Hospital of Shengli Oil Field, Dongying 257034, Shandong Province, China.
authors.forename: Guang
authors.initials: G
authors.lastname: Lu
authors.affiliation: Department of Hematology, The Central Hospital of Shengli Oil Field, Dongying 257034, Shandong Province, China.
authors.forename: Liang
authors.initials: L
authors.lastname: Wang
authors.affiliation: Department of Hematology, The Central Hospital of Shengli Oil Field, Dongying 257034, Shandong Province, China. E-mail: 18054618175@163.com.
authors.forename: Guo-Qiang
authors.initials: GQ
authors.lastname: Liu
mesh_terms: D064987:Cell- and Tissue-Based Therapy; D055612:Cytokine-Induced Killer Cells / Q000166:cytology*; D003713:Dendritic Cells / Q000166:cytology*; D006801:Humans; D016219:Immunotherapy, Adoptive; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000628:therapy*; D050378:T-Lymphocytes, Regulatory / Q000166:cytology; D016896:Treatment Outcome